Dennis J. Slamon, MD, PhD
Although PARP inhibitors were intended to treat patients who harbor germline BRCA
mutations, Dennis J. Slamon, MD, PhD, explained that the future of PARP inhibition is likely to lie in combination and at full dose.
Niraparib (Zejula), for example, has shown efficacy in patients with platinum-resistant/refractory ovarian cancer when in combination with pembrolizumab (Keytruda). Data from the recurrent ovarian cancer cohort of the phase I/II TOPACIO/KEYNOTE-162 trial showed an objective response rate of 25% and disease control rate of 67% in the 60 evaluable patients.
... to read the full story